Rapport Therapeutics, Inc. Common Stock (RAPP) Earnings History
Net Loss4 years of earnings data (2022–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Rapport Therapeutics, Inc. Common Stock (RAPP) Earnings Overview
As of October 3, 2026, Rapport Therapeutics, Inc. Common Stock (RAPP) reported trailing twelve-month net income of -$137M, reflecting +24.3% year-over-year growth. The company earned $-2.89 per diluted share over the past four quarters.
Looking at the long-term picture, RAPP's historical earnings data spans multiple years. The company achieved its highest annual net income of -$11M in fiscal 2022.
Rapport Therapeutics, Inc. Common Stock is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PTCT (-$38M net income, 39.4% margin), ACAD ($380M net income, 36.5% margin), PRAX (-$339M net income), RAPP has comparable earnings metrics. Compare RAPP vs PTCT →
RAPP Earnings vs Peers
Earnings metrics vs comparable public companies
RAPP Historical Earnings Data (2022–2025)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$111M | -42.4% | -$125M | $-2.86 | - | - |
| 2024 | -$78M | -125.1% | -$83M | $-3.78 | - | - |
| 2023 | -$35M | -226.6% | -$36M | $-0.95 | - | - |
| 2022 | -$11M | - | -$10M | $-0.29 | - | - |
Download Data
Export RAPP earnings history in CSV or JSON format
Free sign-in required to download data
RAPP Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
RAPP — Frequently Asked Questions
Quick answers to the most common questions about buying RAPP stock.
What is RAPP earnings per share (EPS)?
RAPP trailing twelve-month (TTM) diluted EPS is $-2.89, reflecting +24.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2022 to 2025 is available in the table on this page.
What is Rapport Therapeutics, Inc. Common Stock's net income?
Rapport Therapeutics, Inc. Common Stock (RAPP) trailing twelve-month net income is $-137M as of 2025. Earnings grew +24.3% year-over-year.
Is RAPP profitable?
RAPP is not currently profitable on a TTM basis, reporting a net loss of $-137M. Net margin is N/A. Investors should monitor for a return to profitability.
What is RAPP's earnings growth rate?
RAPP compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2022 to 2025.
What are RAPP's profit margins?
Rapport Therapeutics, Inc. Common Stock net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -28.2%.
Is RAPP growing earnings?
Yes, RAPP earnings are accelerating — EPS growth of +24.3% exceeds the 5-year CAGR of N/A. TTM net income reached $-137M. Earnings momentum is strengthening.
What was RAPP's best earnings year?
Rapport Therapeutics, Inc. Common Stock's highest annual net income on record is $-11M, achieved in fiscal year 2022. Earnings history on this page spans 2022 to 2025 and includes all annual and quarterly figures.
What were RAPP's earnings last quarter?
RAPP's most recent reported quarter was Q2 2026. Net income was $-57M with diluted EPS of $-1.19. For a full breakdown of all quarters, see the quarterly earnings table on this page.